Abstract
Mafosfamide is a cyclophosphamide analog which, unlike cyclophosphamide, does not require enzymatic activation and does not cause urinary tract toxicity. Administration of mafosfamide intraperitoneally, but not intravenously, causes a delayed, dose-dependent fibrotic peritoneal reaction associated with an increased incidence of delayed mortality. This phenomenon might complicate interpretation of in vivo laboratory studies of activity and toxicity in which the intraperitoneal route of administration is utilized. Further, this toxic effect presents a problem for the clinical development of this agent for regional therapies such as intraperitoneal installation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
